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Abstract
Background Longitudinal cohort studies provide important information about the clinical effectiveness of an intervention 
in the routine clinical setting, and are an opportunity to understand how a population presents for treatment and is managed.
Methods INTEREST IN CD2 (NCT01753349) is a prospective, international, 3-year, longitudinal, observational study 
following the course of adult idiopathic cervical dystonia (CD) treated with botulinum neurotoxin type A (BoNT-A). The 
primary objective is to document long-term patient satisfaction with BoNT-A treatment. Here we report baseline data.
Results This analysis includes 1036 subjects (67.4% of subjects were female; mean age was 54.7 years old; mean TWSTRS 
Total score was 31.7). BoNT-A injections were usually given in line with BoNT-A prescribing information. The most com-
monly injected muscles were splenius capitis (87.3%), sternocleidomastoid (82.6%), trapezius (64.3%), levator scapulae 
(40.9%) and semispinalis capitis (26.9%); 35.5% of subjects were injected using a guidance technique. Most subjects (87.8%) 
had been previously treated with BoNT-A (median interval between last pre-study injection and study baseline was 4 months); 
of these 84.8% reported satisfaction with BoNT-A treatment at peak effect during their previous treatment cycle and 51.5% 
remained satisfied at the end of the treatment. Analyses by geographical region revealed heterogeneity in the clinical char-
acteristics and BoNT-A injection practice of CD subjects presenting for routine treatment.
Conclusions These baseline analyses provide sizeable data regarding the epidemiology and clinical presentation of CD, 
and demonstrate an international heterogeneity of clinical practice. Future longitudinal analyses of the full 3-year study will 
explore how these factors impact treatment satisfaction.
Keywords Botulinum toxin · Cervical dystonia · Observational study · Tremor
Introduction
Cervical dystonia (CD) is the most common form of focal 
dystonia in adults and is primarily characterised by twist-
ing or turning of the neck causing an abnormal head posi-
tion [1–3]. Disability with functional impairment, pain, and 
embarrassment with social withdrawal are also frequent fea-
tures of CD and several studies have shown that it can have 
a negative impact on quality of life [4–7]. Treatment guide-
lines recommend injections of botulinum neurotoxin type 
A (BoNT-A) as first-line treatment for primary CD [8, 9]. 
However, there is little data on how BoNT-A injections for 
CD are administered in routine clinical practice (e.g. dose, 
duration of effect, choice of muscles to inject, and targeting 
technique) nor is there robust information on the long-term 
natural history of CD in patients undergoing treatment.
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It is increasingly recognised that while placebo-controlled 
trials remain the gold standard in assessing response to a 
therapeutic intervention, they do not provide adequate infor-
mation of clinical effectiveness and safety of an intervention 
in the typical clinical setting. In particular, such trials typi-
cally employ narrow inclusion and exclusion criteria, and 
assess only a restricted selection of endpoints. Consequently, 
they do not provide the answers to many key questions, such 
as which patients are most likely to benefit from treatment 
and in what way. Large multicentre longitudinal cohort stud-
ies conducted in a routine clinical practice setting are nec-
essary to answer these important questions. Moreover, for 
generalisability across diverse populations such studies need 
to have an international geographical representation.
The INTEREST IN CD programme was, therefore, 
designed to generate real-life data to confirm effectiveness 
and safety of BoNT-A in routine practice and to create a 
common language to share knowledge and best practice 
among physicians and patients. The first study in the pro-
gramme (INTEREST IN CD1) followed 404 subjects (9 
countries) over 1 injection cycle and demonstrated that 
patient satisfaction is an important and appropriate measure 
of BoNT-A response in CD subjects [10]. As well as placing 
greater emphasis on real-world evidence, many regulators 
and payers now place greater emphasis on patient reported 
outcomes (PROs) [11, 12], and these organisations often 
give prominence to the patient voice. Patient satisfaction 
with treatment is considered especially important as this has 
been shown to directly correlate with willingness to continue 
treatment [13, 14]. The INTEREST IN CD2 study was sub-
sequently designed to evaluate the effectiveness of repeated 
injections of BoNT-A in routine practice. The primary 
objective of this larger and longer study was to document 
the effect of BoNT-A treatment upon long-term patient sat-
isfaction with respect to the control of symptoms associated 
with idiopathic CD.
We report here the baseline characteristics of the INTER-
EST IN CD2 cohort, which is the largest study in CD to 
date and was conducted across six continents. While payers 
have long recognised the need to understand how a clinical 
population presents for treatment and is managed, clinicians 
are only starting to understand the relevant insights that real-
world studies such as INTEREST IN CD2 can provide [15]. 
In particular, the scope of the database allowed us to explore 
the commonalities and differences in international treatment 
practices, not only in terms of patient presentation, but also 
injection practice. In addition, the collection of such a stand-
ardised and comprehensive dataset also allows interrogation 
of emerging scientific hypotheses, such as understanding the 
association between tremor (often a key clinical component 
of CD) and other CD symptoms.
Methods
INTEREST IN CD2 (NCT01753349) is an ongoing 3-year 
multicentre longitudinal cohort study following the course of 
adult idiopathic CD patients treated with BoNT-A. The study 
was conducted in compliance with the International Soci-
ety for Pharmacoepidemiology (ISPE) Guidelines for Good 
Pharmacoepidemiology Practices (GPP) [16]; it began on 
10 December 2012 and last visit of the last patient occurred 
on 25 September 2017. Participating centres needed to be 
familiar with Toronto Western Spasmodic Torticollis Rating 
Scale (TWSTRS) and Tsui scales in their clinical practice. 
To limit the potential bias that might be introduced by over-
recruiting sites, the number of subjects was limited to 12 
consecutive subjects per centre. Independent Ethics Com-
mittee/Institutional Review Board approval was obtained 
prior to each centre initiation. Written informed consent 
was obtained prior to subject enrolment and prior to any 
data collection.
Population
This study enrolled adult subjects (≥ legal age in each coun-
try) with primary CD presenting for treatment with BoNT-A 
in routine clinical practice. Subjects could be treated with 
any BoNT-A formulation. The decision to prescribe a BoNT-
A preparation was taken prior to, and independently from, 
the decision to enrol the subject in the study. Subjects could 
be new to BoNT-A treatment or previously treated with 
BoNT-A, provided there had been at least a 12-week inter-
val between the last injection and study entry. Recruitment 
completed on 31 July 2014, and here we report subjects’ 
baseline data (baseline visit = Visit 1).
Assessments
All subjects underwent a comprehensive clinical CD 
assessment at baseline/first injection visit. An electronic 
case report form (eCRF) was utilised for data collection, 
including data on medical history, treatment history, and 
full details of first injection given (muscles selected, injected 
dose, injected volume, number of injection sites, use of 
injection guidance technique). Subjects were also assessed 
using the TWSTRS [17] and Tsui scale (tremor component) 
[18].
Subjects previously treated with a BoNT-A reported 
their satisfaction from last BoNT-A treatment in two ways: 
(1) their highest level of satisfaction at any time since the 
last BoNT-A injection and (2) satisfaction at the time of the 
visit (i.e. baseline visit of the study). Both types of satisfac-
tion were rated on a 5-point Likert scale (1—completely 
404 Journal of Neurology (2018) 265:402–409
1 3
satisfied; 2—rather satisfied; 3—neither satisfied nor dis-
satisfied; 4—rather dissatisfied; 5—completely dissatisfied).
Statistical analyses
All analyses of baseline data were made under the guidance 
of the INTEREST IN CD2 Scientific Committee who regu-
larly met at face-to-face meetings with the Study Team to 
review trial progress and predefined analyses of interest from 
the comprehensive dataset. For the purposes of evaluating 
international differences in CD management, the participat-
ing countries were grouped into six regions: Asia, Australia, 
Europe, Latin America, North Africa/Middle East and the 
United States of America (USA).
The statistical analyses of this report are primarily 
descriptive. Mean and standard deviation (mean ± SD) or 
median measures were used to summarise continuous vari-
ables, and absolute and relative frequencies expressed as 
percentage (%) are presented for categorical information. 
Analyses of patient satisfaction with BoNT-A treatment were 
performed in the subgroup of subjects who had previously 
been treated with BoNT-A. Satisfaction was defined as those 
with a score of 1 or 2 (completely satisfied or rather satis-
fied). Associations between Tsui tremor component scores 
and TWSTRS Total and subscale scores were assessed using 
a non-parametric Kendall correlation test and then further 
explored using an analysis of variance.
Results
A total of 1050 subjects were enrolled from 113 active cen-
tres in 34 countries (Online Appendix). Of these, 14 were 
excluded [data not authenticated (n = 7), not injected at Visit 
1 (n = 4), BoNT-B injected at Visit 1 (n = 2), no Visit 1 data 
available (n = 1)] and 1036 subjects were analysed.
Subject characteristics
The 1036 subjects analysed included 143 from Asia (7 
countries), 40 from Australia, 620 from Europe (17 coun-
tries), 82 from Latin America (2 countries), 113 from North 
Africa and the Middle East (6 countries), and 38 from the 
USA. Subject demographics, medical history, and clinical 
severity scores at Visit 1 are presented in Table 1. Most 
subjects were female (67.4% overall), the mean ± SD age 
was 54.7 ± 13.2 years and the majority of patients had rota-
tion (66.7%) or laterocollis (22.5%) as their predominant 
CD pattern.
Treatment of cervical dystonia
Injection parameters are shown in Table 2. Most subjects 
were injected at Visit 1 with abobotulinumtoxinA (n = 723), 
followed by onabotulinumtoxinA (n = 254) and incobotu-
linumtoxinA (n = 59). Approximately one-third (35.5%) of 
subjects were injected using a guidance technique, however, 
there was wide variation between geographical regions. 
Most guided injections (all regions) were performed using 
electromyography (EMG, used in 335 of 1036 subjects), 
while 34 used ultrasound, three electrostimulation and one 
computed tomography guidance. It was observed that use 
of injection guidance techniques appeared to be an ‘all or 
nothing’ practice (i.e. either all muscles or no muscles were 
injected using a guidance technique).
More than 17 different muscles were reported as injected 
by investigators at baseline. The five most commonly 
injected muscles were the splenius capitis (87.3% of all sub-
jects), sternocleidomastoid (82.6%), trapezius (64.3%), leva-
tor scapulae (40.9%) and semispinalis capitis (26.9%). Injec-
tion details for those muscles across all regions are given in 
the Supplementary Appendix. The scalene group (scalenus 
anterior, posterior and medium) was injected in 16.4% of 
subjects and other muscles [including the longissimus group 
(longissimus cervicis, and capitis), oblique capitis group 
(obliquus capitis inferior, superior and transverse), platy-
sma, splenius cervicis, longus capitis, rectus capitis group 
(rectus capitis lateralis, posterior major and posterior minor), 
interspinalis cervicis and longus colli] were injected with a 
frequency of between 0.2 and 5.0%.
Satisfaction with previous treatment (previously 
treated subgroup)
Of the 1036 subjects analysed, 910 were previously treated 
with BoNT-A and included in this analysis of treatment 
satisfaction. More subjects had previously been injected 
with abobotulinumtoxinA compared to onabotulinumtox-
inA and incobotulinumtoxinA (64.0 vs. 27.9 and 7.4%, 
respectively; 0.8% on other BoNT-A). The median time 
from starting BoNT-A treatment in previously BoNT-
treated subjects was 67.1 months [range 2.3–357.0] and 
the median interval between the last pre-study injection 
visit and study Visit 1 was 3.6 months [range 1.8–191.5]. 
The length of treatment interval between the last pre-
study injection visit and study Visit 1 differed consider-
ably between regions. For example, whereas most subjects 
in USA and Australia (81 and 64%, respectively) were 
re-treated with BoNT-A within 12–16 weeks, most in 
Latin America and Asia (81 and 73%, respectively) had 
an injection interval of > 16 weeks. About half in Europe 
and North Africa/Middle East (52 and 57%, respec-
tively) were treated with an interval of 12–16 weeks and 
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a slightly smaller proportion was treated with an interval 
of > 16 weeks (45 and 42%, respectively). Less than 3% 
in all regions were treated with an interval of < 12 weeks. 
Taken overall, 49% of subjects had an injection interval 
between last BoNT injection prior to study entry and Visit 
1 which was > 16 weeks, 48% between 12 and 16 weeks 
and 2% < 12 weeks.
Figure 1 shows that while 84.8% subjects reported they 
had been completely/rather satisfied with treatment at peak 
effect during their previous treatment cycle, fewer (51.5%) 
reported satisfaction at the end of the treatment cycle (i.e. 
first study visit). Similar results were seen for all subjects, 
regardless of the length of the previous treatment interval.
Table 1  Demographic, medical history and clinical characteristics at baseline
Asia: China, Malaysia, Republic of Korea, Singapore, Taiwan, Thailand, The Philippines; Australia; Europe: Austria, Belgium, Czech Republic, 
Estonia, France, Germany, Hungary, Italy, Latvia, Poland, Portugal, Romania, Russia, Serbia, Slovenia, Sweden, United Kingdom; Latin Amer-
ica: Brazil, Mexico; North Africa and Middle East: Algeria, Israel, Jordan, Lebanon, Turkey, United Arab Emirates; United States of America 
(USA)
CD cervical dystonia, SD standard deviation, TWSTRS Toronto Western Spasmodic Torticollis Rating Scale, USA United States of America
a Missing data in two subjects from Europe
b Missing data for TWSTRS in one subject from Australia and for Tsui in two subjects from Europe
Asia (N = 143) Australia (N = 40) Europe (N = 620) Latin America 
(N = 82)
North Africa/ Mid-
dle East (N = 113)
USA (N = 38) Overall 
(N = 1036)
Demographics
Sex
 Female; n (%) 80 (55.9) 32 (80.0) 430 (69.4) 52 (63.4) 71 (62.8) 33 (86.8) 698 (67.4)
Age (years); 
mean ± SD
55.0 ± 13.5 61.7 ± 12.4 54.7 ± 12.7 56.6 ± 13.6 48.4 ± 13.7 60.3 ± 11.4 54.7 ± 13.2
Medical history
Proportion subjects 
with CD family 
history; n (%)
3 (2.1) 9 (22.5) 36 (5.8) 5 (6.1) 12 (10.6) 3 (7.9) 68 (6.6)
Time since diag-
nosis (years); 
median [range]
6.0 [0.0–29.0] 5.0 [0.0–36.0] 6.0 [0.0–49.0] 7.0 [0.0–57.0] 6.0 [0.0–57.0] 10.0 [0.0–29.0] 6.0 [0.0–57.0]
Predominant head/neck deviation pattern and associated componentsa
Rotation; n (%) 91 (63.6) 31 (77.5) 418 (67.6) 42 (51.2) 75 (66.4) 33 (86.8) 690 (66.7)
Laterocollis; n (%) 33 (23.1) 4 (10.0) 146 (23.6) 24 (29.3) 24 (21.2) 2 (5.3) 233 (22.5)
Retrocollis; n (%) 9 (6.3) 3 (7.5) 28 (4.5) 12 (14.6) 9 (8.0) 1 (2.6) 62 (6.0)
Anterocollis; n (%) 4 (2.8) 1 (2.5) 10 (1.6) 3 (3.7) 2 (1.8) 0 (0) 20 (1.9)
Lateral shift; n (%) 4 (2.8) 0 (0) 8 (1.3) 1 (1.2) 1 (0.9) 1 (2.6) 15 (1.5)
Sagittal shift; n (%) 2 (1.4) 0 (0) 5 (0.8) 0 (0) 2 (1.8) 1 (2.6) 10 (1.0)
Shoulder elevation; 
n (%)
91 (63.6) 9 (22.5) 263 (42.6) 64 (78.0) 71 (62.8) 19 (50.0) 517 (50.0)
Tremor; n (%) 53 (37.1) 29 (72.5) 288 (46.6) 56 (68.3) 55 (48.7) 18 (47.4) 499 (48.3)
Jerk; n (%) 12 (8.4) 6 (15.0) 48 (7.8) 20 (24.4) 6 (5.3) 7 (18.4) 99 (9.6)
Clinical rating scale scoresb
TWSTRS Total; 
mean ± SD
32.1 ± 11.9 26.7 ± 12.7 30.5 ± 12.6 39.7 ± 14.2 33.2 ± 14.1 32.5 ± 14.4 31.7 ± 13.1
TWSTRS Severity; 
mean ± SD
16.9 ± 4.9 13.2 ± 5.1 15.4 ± 5.7 19.2 ± 5.4 16.5 ± 6.0 14.4 ± 5.1 15.9 ± 5.7
TWSTRS Disabil-
ity; mean ± SD
8.6 ± 6.2 6.7 ± 5.8 9.3 ± 6.1 10.9 ± 7.2 10.5 ± 6.8 11.9 ± 6.6 9.4 ± 6.3
TWSTRS Pain; 
mean ± SD
6.5 ± 4.9 6.8 ± 5.1 5.8 ± 4.6 9.7 ± 5.3 6.3 ± 4.8 6.2 ± 5.3 6.3 ± 4.9
Tsui tremor score category; n (%)
0 73 (51.0) 8 (20.0) 255 (41.3) 23 (28.0) 50 (44.2) 17 (44.7) 426 (41.2)
1 40 (28.0) 15 (37.5) 183 (29.6) 23 (28.0) 36 (31.9) 9 (23.7) 306 (29.6)
2 18 (12.6) 8 (20.0) 109 (17.6) 26 (31.7) 11 (9.7) 5 (13.2) 177 (17.1)
4 12 (8.4) 9 (22.5) 71 (11.5) 10 (12.2) 16 (14.2) 7 (18.4) 125 (12.1)
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Association of tremor with CD severity
Non-parametric correlation analysis (based on the total 
population, n = 1036) found a weak association between 
tremor and TWSTRS Severity. The Kendall’s coefficient 
was 0.057 with a p value of 0.02 (Table 3). Further evalua-
tion using an analysis of variance revealed that subjects with 
a Tsui score of 4 had significantly higher TWSTRS Total 
and Severity scores versus subjects with lower Tsui scores 
(0–2), P < 0.01. No other statistically significant associa-
tions between Tsui tremor component scores and TWSTRS 
Total & subscale scores were observed (all correlation coef-
ficients were < 0.1).
Discussion
To the best of our knowledge, INTEREST IN CD2 is the 
largest study ever conducted in a population of treated CD 
patients and our data clearly showcase the utility and impor-
tance of conducting large multicentre longitudinal cohort 
studies. In terms of clinical characteristics, the baseline data-
base provides new insights into regional differences in the 
way patients present for routine treatment for BoNT-A injec-
tions. For example, the data showed that subjects in Latin 
America had the highest TWSTRS Total scores (mean of 
39.7), driven by high TWSTRS Pain scores. Likewise, while 
USA subjects had relatively low TWSTRS Severity scores 
Table 2  Overall BoNT-A injection parameters at baseline
BoNT-A botulinum neurotoxin type A, mL millilitre, U units, USA United States of America
Asia (N = 143) Australia 
(N = 40)
Europe 
(N = 620)
Latin America 
(N = 82)
North Africa/ 
Middle East 
(N = 113)
USA (N = 38) Overall 
(N = 1036)
Injected volume 
(mL); median 
[range]
2.00 [0.3–8.0] 1.60 [0.3–7.0] 2.00 [0.2–12.5] 2.65 [0.3–10.0] 2.80 [0.2–7.4] 3.00 [1.0–6.0] 2.00 [0.2–12.5]
Number of injec-
tion points; 
median [range]
8.0 [2–24] 5.5 [2–23] 6.0 [1–28] 8.5 [1–34] 8.0 [1–24] 9.0 [2–30] 7.0 [1–34]
Use of injection 
guidance; n 
(%)
41 (28.7) 37 (92.5) 191 (30.8) 4 (4.9) 72 (63.7) 23 (60.5) 368 (35.5)
BoNT-A dose (U); median [range]
 Abobotulinum-
toxinA
N = 111
440 [50–800]
N = 17
500 [170–1050]
N = 428
500 [70–1300]
N = 72
500 [50–1700]
N = 77
620 [90–1480]
N = 18
600 [350–1000]
N = 723
500 [50–1700]
 Incobotulinum-
toxinA
–
–
–
–
–
–
N = 44
177.5 [50–500]
N = 6
245 [170–330]
–
–
–
N = 9
400 [150–500]
N = 59
200 [50–500]
 Onabotulinum-
toxinA
N = 32
125 [40–250]
N = 23
170 [75–350]
N = 148
145 [10–475]
N = 4
250 [100–300]
N = 36
200 [100–380]
N = 11
225 [100–500]
N = 254
150 [10–500]
Fig. 1  Subject satisfaction with 
BoNT-A treatment in BoNT 
previously treated subjects at 
baseline. *Missing data in one 
subject from the 12–16 weeks 
population. **Injection interval 
between last BoNT injection 
prior to study entry and baseline 
visit was unknown in four sub-
jects, however, the satisfaction 
rating was available for them. 
BoNT botulinum neurotoxin, 
BoNT-A botulinum neurotoxin 
type A
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(mean of 14.4), ratings of TWSTRS Disability were notice-
ably higher in the USA (mean of 11.9) than all other regions. 
Such observations may indicate cultural differences in the 
way CD patients experience their symptoms. However, it is 
also interesting to note the wide variance in the proportion 
of females across the regions (from 55.9% representation 
in Asia to 86.8% representation in the USA) and that sub-
jects recruited from Australia reported a higher proportion 
of other family members with CD (22.5 vs. < 11% in other 
regions). While we cannot rule out possible subject selection 
bias in the different countries and regions, our data highlight 
a need to further evaluate the impact of regional differences 
in epidemiological studies investigating age of onset, gender 
and other differences.
The data generated for injection practice demonstrates 
that BoNT-A injections are usually given in line with the 
prescribing information for each product. The predominance 
in use of abobotulinumtoxinA in this study may reflect a 
site selection bias, but it should be noted that half (50%) of 
all sites used more than one product in their patient popula-
tion. The most commonly injected muscles were appropriate 
for the most common head/neck deviation patterns (namely, 
rotational torticollis and laterocollis). While there was com-
monality across the regions in terms of muscle selection, 
injection volumes and number of injection sites, there was 
a striking difference in the use of guidance techniques. This 
likely reflects the training of injecting clinicians as well as 
access to equipment. To date, there has been no evidence that 
use of guidance techniques is required for every patient, and 
our data appears to support the idea that many injectors feel 
confident without them. However, we point out that studies 
have shown that use of a guidance technique improves the 
safety of injections in patients with complex presentation 
and with previous experience of adverse events such as dys-
phagia [19]. Injections of deeper and thinner muscles (such 
as the levator scapulae and oblique capitis group) often also 
require injection guidance for accuracy [20].
The INTEREST IN CD1 study [10] demonstrated that 
patient satisfaction with treatment is a valuable measure of 
treatment efficacy. Recent surveys have demonstrated that 
patients have very high expectations for their treatment, with 
over 60% of patients expecting freedom from spasms and/
or freedom from pain and over half expecting to be able to 
return to a normal routine [7]. As might be expected, overall 
satisfaction in subjects who had been treated with BoNT for 
a median of 5.5 years was high, with 84.8% of BoNT previ-
ously treated subjects reporting that they were completely or 
rather satisfied with their previous treatment at peak effect. 
Satisfaction with treatment on the day of the clinic visit was 
lower (51.5%) because in most cases at least 12 weeks had 
passed since the last injection and thus the effects of the last 
injection were wearing-off or had worn off. Unlike previous 
studies [21], we observed no differences in the rate of satis-
faction (at peak effect or at the time of visit) when subjects 
were categorised according to the length of their prior treat-
ment interval; patients with an injection interval > 16 weeks 
appeared to be as equally highly satisfied as those re-injected 
with a 12–16 week interval. It should be noted that the num-
bers of subjects with an injection interval of < 12 weeks was 
too low to draw any conclusions about this short interval. 
Our assessment of patient satisfaction asked patients to rate 
their overall ‘control of symptoms’, and did not consider 
practical ‘health economic’ aspects, such as costs associ-
ated with more frequent visits and more frequent injections, 
that will also affect the patient. For those clinics which must 
follow a longer than 16-week schedule (e.g. due to reim-
bursement plans), it may be that a longer lasting toxin for-
mulations would be beneficial—especially as it is clear that 
satisfaction drops at the end of a treatment cycle.
Updated consensus guidelines for dystonia now empha-
sise the importance of assessing tremor [22], as an integral 
feature of this disorder; however, its relationship to other 
symptoms of CD has not been well studied. Tremor in dys-
tonia usually manifests during posture or voluntary move-
ments, although some dystonic patients may have tremor 
at rest. Neurophysiological investigations in patients 
with dystonia (including CD) and tremor show a lack of 
brainstem interneuronal inhibition, and abnormal sensory 
integration [23]. Using the unique opportunities provided 
by the large dataset, we were able to examine whether 
tremor correlates with other CD symptoms or if it is an 
independent symptom of CD. In our analyses, the only 
statistically significant correlation between tremor and CD 
was a possible association between mean TWSTRS Sever-
ity subscore and Tsui tremor severity subscore. However, 
this association was weak, and the data taken in totality 
suggest that tremor is an independent symptom of CD (i.e. 
the severity of tremor does not predict severity of CD).
We believe that the strengths of this study include its 
size, truly global nature and inclusion of all BoNT-A 
products. Other studies have been restricted to one prod-
uct and often one country [24–26]. The study has several 
Table 3  Kendall correlation tests between TWSTRS scores and Tsui 
tremor scores
TWSTRS Toronto Western Spasmodic Torticollis Rating Scale
Correlation tested Kendall’s 
tau-b coef-
ficient
P value
TWSTRS Total score and Tsui tremor score 0.040 0.09
TWSTRS Severity score and Tsui tremor 
score
0.057 0.02
TWSTRS Disability score and Tsui tremor 
score
0.027 0.27
TWSTRS Pain score and Tsui tremor score 0.019 0.43
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limitations including smaller subject numbers in certain 
regions and site selection bias. Our exploratory ‘regional’ 
analyses were performed to look for any international 
heterogeneity of practice; this sometimes required group-
ing together countries with distinct socio-economic dif-
ferences to have reasonable sample sizes. Other methods 
of categorisation could also be of relevance (e.g. by type 
of healthcare system) and should be analysed in future 
studies. This is in addition to those limitations inherent 
to all open-label observational studies. The present report 
is limited to baseline data, but future data-sets from the 
study will provide important information about the impact 
of BoNT-A treatment on the natural history of treated CD 
(i.e. effectiveness of treatment). Longitudinal subgroup 
analyses of subjects who were new to BoNT-A treatment 
will be of particular interest in defining the impact of mod-
ern treatment practices on the natural history of CD. We 
plan to further assess possible predictors of patient satis-
faction with treatment, evolution of patient satisfaction 
after repeated BoNT-A treatment cycles, and how treat-
ment intervals relate to patient satisfaction. One of the 
key aims of the programme is to share of best practice, 
and we believe the data presented here will be of practical 
relevance to BoNT-A injectors.
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